PDF
Cite
Share

facebook

twitter

google

linkedin

Volume 41 Issue 11

Nov. 2025

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2025 > 41(11): 2286-2293

Influence of SH2B1rs7359397 polymorphism on hepatic fibrosis in patients with metabolic dysfunction-associated steatotic liver disease aged ≥65 years in Beijing， China

DOI: 10.12449/JCH251114

1.
Third Department of Liver Disease Center，Beijing YouAn Hospital，Capital Medical University，Beijing 100069，China
2.
Inpatient Ward，Mentougou Kuangshan Hospital，Beijing Jingmei Group General Hospital，Beijing 100069，China

Research funding:

National Science and Technology Major Project of China (2023ZD0508703);

Capitalss Funds for Health Improvement and Research (2022-2Z-2187);

Beijing High-Level Public Health Technical Talent Construction Project (Beijing Municipal Hospital Administration 03-23)

More Information

Corresponding author: ZHANG Jing， zjyouan@ccmu.edu.cn （ORCID： 0000-0002-3082-8330）
Received Date: 2025-02-10
Accepted Date: 2025-04-07
Published Date: 2025-11-25

Abstract

Objective To investigate the association of SH2B1 rs7359397 （C>T） polymorphism with the progression to hepatic fibrosis in the elderly patients with metabolic dysfunction-associated steatotic liver disease （MASLD） in Beijing， China， and to provide an important genetic basis for the precise subtyping， prognostic evaluation， and individualized treatment of elderly MASLD patients in China. Methods A total of 505 elderly patients （aged ≥65 years） who participated in regular physical examination in Mentougou Kuangshan Hospital of Beijing Jingmei Group General Hospital from November 2020 to September 2021 and were diagnosed with MASLD by abdominal ultrasound were enrolled as MASLD group， and 381 elderly population who underwent physical examination in the same community hospital during the same period of time and were not found to have MASLD by abdominal ultrasound were enrolled as control group. FibroScan was used to measure liver fat content and determine fibrosis stage. The 96-well microfluidic chip technique was used to identify SH2B1rs7359397 polymorphism. The independent-samples t test was used for comparison of normally distributed continuous data between the two groups， and the chi-square test or the adjusted chi-square test was used for comparison of categorical data between the two groups. Univariate and multivariate Logistic regression analyses were used to identify the independent predictive factors for MASLD and its comorbidities. Results Compared with the control group， the MASLD group had a significantly younger age and significantly higher levels of waist circumference， hip circumference， waist-hip ratio， body mass index （BMI）， alanine aminotransferase， aspartate aminotransferase， triglyceride， platelet count， and fibrosis-4 （FIB-4） index， as well as a significantly lower level of high-density lipoprotein cholesterol （all P<0.05）. Among the 381 patients in the control group， 264 （69.29%） had genotype CC and 117 （30.71%） had genotype CT+TT， while among the 505 patients in the MASLD group， 317 （62.77%） had genotype CC and 188 （37.23%） had genotype CT+TT， suggesting that the MASLD group had a significantly higher proportion of patients with genotype CT+TT compared with the control group （χ²=4.09， P=0.043）. In the MASLD group， compared with the genotype CC group， the genotype CT+TT group had a significantly lower proportion of patients with FIB-4 ≥2 or atherosclerotic cardiovascular diseases （P<0.05）. The multivariate Logistic regression analysis showed that after adjustment for age， sex， and BMI， carrying T allele was a protective factor against progressive hepatic fibrosis （odds ratio ［OR］=0.481， 95% confidence interval ［CI］： 0.249 — 0.929， P=0.029）. In the subgroups of comorbidities with hypertension， metabolic syndrome， and obesity， genotype CT+TT was associated with a significant reduction in the risk of progressive hepatic fibrosis （hypertension： OR=0.27， 95%CI：0.09 — 0.77， P=0.014； metabolic syndrome： OR=0.30， 95%CI： 0.11 — 0.79， P=0.015； obesity： OR=0.11， 95%CI： 0.03 — 0.48， P=0.003）. After adjustment for age， sex， and BMI， in the patients with MASLD， the patients with genotype CT+TT had a significant reduction in the prevalence rate of atherosclerotic cardiovascular diseases compared with those with genotype CC （OR=0.506， 95%CI：0.336 — 0.761， P=0.001）. Conclusion SH2B1rs7359397 （C>T） polymorphism is associated with the reduction in the risk of hepatic fibrosis and atherosclerotic cardiovascular diseases in MASLD patients.
- Metabolic Dysfunction-Associated Steatotic Liver Disease,
- Hepatic Fibrosis,
- Genetic Predisposition to Disease,
- Cardiovascular Diseases

References

[1]	European Association for the Study of the Liver(EASL); European Association for the Study of Diabetes(EASD); European Association for the Study of Obesity(EASO). EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease(MASLD)[J]. J Hepatol, 2024, 81( 3): 492- 542. DOI: 10.1016/j.jhep.2024.04.031.
[2]	GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet Gastroenterol Hepatol, 2020, 5( 3): 245- 266. DOI: 10.1016/S2468-1253(19)30349-8.
[3]	YOUNOSSI ZM, GOLABI P, PAIK JM, et al. The global epidemiology of nonalcoholic fatty liver disease(NAFLD) and nonalcoholic steatohepatitis(NASH): A systematic review[J]. Hepatology, 2023, 77( 4): 1335- 1347. DOI: 10.1097/HEP.0000000000000004.
[4]	LI M, XIE W. Are there all-cause mortality differences between metabolic dysfunction-associated steatotic liver disease subtypes?[J]. J Hepatol, 2024, 80( 2): e53- e54. DOI: 10.1016/j.jhep.2023.07.012.
[5]	QUEK J, CHAN KE, WONG ZY, et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: A systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2023, 8( 1): 20- 30. DOI: 10.1016/S2468-1253(22)00317-X.
[6]	MAHFOOD HADDAD T, HAMDEH S, KANMANTHAREDDY A, et al. Nonalcoholic fatty liver disease and the risk of clinical cardiovascular events: A systematic review and meta-analysis[J]. Diabetes Metab Syndr, 2017, 11( Suppl 1): S209- S216. DOI: 10.1016/j.dsx.2016.12.033.
[7]	VALENTI LVC, BASELLI GA. Genetics of nonalcoholic fatty liver disease: A 2018 update[J]. Curr Pharm Des, 2018, 24( 38): 4566- 4573. DOI: 10.2174/1381612825666190119113836.
[8]	ROMEO S, KOZLITINA J, XING C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease[J]. Nat Genet, 2008, 40( 12): 1461- 1465. DOI: 10.1038/ng.257.
[9]	LI XY, LIU Z, LI L, et al. TM6SF2 rs58542926 is related to hepatic steatosis, fibrosis and serum lipids both in adults and children: A meta-analysis[J]. Front Endocrinol(Lausanne), 2022, 13: 1026901. DOI: 10.3389/fendo.2022.1026901.
[10]	CHERUBINI A, CASIRATI E, TOMASI M, et al. PNPLA3 as a therapeutic target for fatty liver disease: The evidence to date[J]. Expert Opin Ther Targets, 2021, 25( 12): 1033- 1043. DOI: 10.1080/14728222.2021.2018418.
[11]	ABUL-HUSN NS, CHENG XP, LI AH, et al. A protein-truncating HSD17B13 variant and protection from chronic liver disease[J]. N Engl J Med, 2018, 378( 12): 1096- 1106. DOI: 10.1056/NEJMoa1712191.
[12]	MERONI M, LONGO M, FRACANZANI AL, et al. MBOAT7 down-regulation by genetic and environmental factors predisposes to MAFLD[J]. EBioMedicine, 2020, 57: 102866. DOI: 10.1016/j.ebiom.2020.102866.
[13]	JAMSHIDI Y, SNIEDER H, GE DL, et al. The SH2B gene is associated with serum leptin and body fat in normal female twins[J]. Obesity(Silver Spring), 2007, 15( 1): 5- 9. DOI: 10.1038/oby.2007.637.
[14]	PEREZ-DIAZ-DEL-CAMPO N, ABETE I, CANTERO I, et al. Association of the SH2B1 rs7359397 gene polymorphism with steatosis severity in subjects with obesity and non-alcoholic fatty liver disease[J]. Nutrients, 2020, 12( 5): 1260. DOI: 10.3390/nu12051260.
[15]	PEREZ-DIAZ-DEL-CAMPO N, MARIN-ALEJANDRE BA, CANTERO I, et al. Differential response to a 6-month energy-restricted treatment depending on SH2B1 rs7359397 variant in NAFLD subjects: Fatty Liver in Obesity(FLiO) Study[J]. Eur J Nutr, 2021, 60( 6): 3043- 3057. DOI: 10.1007/s00394-020-02476-x.
[16]	HINNEY A, KÖRNER A, FISCHER-POSOVSZKY P. The promise of new anti-obesity therapies arising from knowledge of genetic obesity traits[J]. Nat Rev Endocrinol, 2022, 18( 10): 623- 637. DOI: 10.1038/s41574-022-00716-0.
[17]	LOOMBA R, ABDELMALEK MF, ARMSTRONG MJ, et al. Semaglutide 2·4 Mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: A randomised, placebo-controlled phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2023, 8( 6): 511- 522. DOI: 10.1016/S2468-1253(23)00068-7.
[18]	PETIT JM, VERGÈS B. GLP-1 receptor agonists in NAFLD[J]. Diabetes Metab, 2017, 43( Suppl 1): 2S28- 2 S 33. DOI: 10.1016/S1262-3636(17)30070-8.
[19]	IWASAKI S, HAMADA T, CHISAKI I, et al. Mechanism-based pharmacokinetic/pharmacodynamic modeling of the glucagon-like peptide-1 receptor agonist exenatide to characterize its antiobesity effects in diet-induced obese mice[J]. J Pharmacol Exp Ther, 2017, 362( 3): 441- 449. DOI: 10.1124/jpet.117.242651.
[20]	MORRIS DL, CHO KW, RUI LY. Critical role of the Src homology 2(SH2) domain of neuronal SH2B1 in the regulation of body weight and glucose homeostasis in mice[J]. Endocrinology, 2010, 151( 8): 3643- 3651. DOI: 10.1210/en.2010-0254.
[21]	ONI ET, AGATSTON AS, BLAHA MJ, et al. A systematic review: Burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care?[J]. Atherosclerosis, 2013, 230( 2): 258- 267. DOI: 10.1016/j.atherosclerosis.2013.07.052.

Relative Articles

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Tables(5)

Get Citation

PDF

XML

Article Metrics

Article views (6) PDF downloads(3)

Proportional views

Related

The first journal specializing in hepatobiliary and pancreatic diseases in China

Supervisor：Ministry of Education of the People's Republic of China

Sponsor：Jilin University

Academic Support: Chinese Society of Hepatology，Chinese Medical Association

Address: 461 Xinjiang Road, Changchun

Submit：0431-88782044

Peer review：0431-88783542

Email：lcgdb@vip.163.com

YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd

/

DownLoad: Full-Size Img PowerPoint